XCUR

ExicureC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$5.20

+64.6% vs current

Most likely

Base case

45%

Probability

Target price

$2.60

-17.7% vs current

B-

Bear case

35%

Probability

Target price

$0.90

-71.5% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment is cautious-to-negative. The strongest primary evidence is the March 25, 2026 10-K, which emphasizes substantial doubt, limited cash, and dependence on added funding or strategic transactions [#10-K-2026-03-25]. The April 10, 2026 8-K adds board and COO appointments with audit, controls, and capital-markets experience, but that reads as operational housekeeping rather than a thesis-changing catalyst by itself [#8-K-2026-04-10]. Given the negative deterministic prior, thin catalyst density, and loose peers, this remains a monitoring-style name rather than a conviction long.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventQ2 2026 GPCR milestone-share issuance could confirm program continuation but add dilution sensitivityHigh impact

The 10-K states Exicure intends to make a $1.0 million milestone payment to GPCR in common stock in the second quarter of 2026 under the License and Collaboration Agreement; completion would signal continued commitment to the GPCR asset, but the stock-settled structure can keep dilution concerns in focus [#10-K-2026-03-25].

2026-06-30catalystFinancing or strategic funding update likely to dominate near-term tapeHigh impact

The 2025 10-K says cash and cash equivalents were about $3.7 million at December 31, 2025, that current liquidity is not sufficient for the next 12 months, and that substantial doubt exists about the company’s ability to continue as a going concern; management also says additional financing or a strategic transaction is needed [#10-K-2026-03-25].

2026-12-31catalystFollow-through on GPCR USA asset and strategic alternatives remains the only credible re-rating pathHigh impact

The 10-K says GPCR USA completed its Phase 2 trial in January 2026 and that Exicure is exploring growth through strategic transactions with potential partners; a concrete partnering, licensing, or development plan around the GPCR program would matter more than governance changes, but visibility is still weak [#10-K-2026-03-25][#8-K-2026-04-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology